Vania Silvestri

Vania Silvestri

Auto-generated profile, based on publicly available information

Vania Silvestri

Department of General and Oncological Minimally Invasive Surgery, University Federico II of Naples, Naples, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
ABAneel Bhangu
Aneel Bhangu
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
MAMaria Lorena Aguilera
Maria Lorena Aguilera
PAPhilip Alexander
Philip Alexander
SASara W Al-Saqqa
Sara W Al-Saqqa
RBRuth Blanco
Ruth Blanco
Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p<0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05-2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p<0·001). Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication. DFID-MRC-Wellcome Trust Joint Global Health Trial Development Grant, National Institute of Health Research Global Health Research Unit Grant.

1 May 2018 in International Journal of Surgery
Verified
Journal Article
Closed access
ARAntonia Rizzuto
Antonia Rizzuto
MPMassimiliano Fabozzi, MD, PhD
Massimiliano Fabozzi, MD, PhD
ASAnna Settembre
Anna Settembre
SRStefano Reggio
Stefano Reggio
ETErnesto Tartaglia
Ernesto Tartaglia
FCFrancesco Corcione
Francesco Corcione
Choledocholithiasis occurs in 10-15% of patients with cholecystolithiasis. Despite the existence of many therapeutic options for the treatment of cholecystocholedocholithiasis, a sequential treatment in which pre-operative ERCP is combined with intraoperative cholangiography (IOC) and laparoscopic cholecystectomy (LC), is the most commonly accepted strategy. However, use of IOC in the "splitting treatment" of cholecystocholedocholithiasis is controversial. The aim of the present study is to investigate the utility of IOC in detecting residual stones in patients undergoing LC in the sequential treatment of common biliary duct or gallbladder stones. Patients were recruited retrospectively among those who underwent IOC during LC, performed as second stage in the sequential treatment for cholecystocholedocholithiasis between 2010 and 2016. Demographic and clinical data were obtained from CPT codes at Ospedale Monaldi A.O.R.N dei Colli Naples, Italy. Data obtained from all pre-operative ERCP analyses were recorded, including cholangiogram findings and performance of sphincterotomy. Statistical analysis was carried out using the IBM SPSS Statistic 19.0 software package. Between January 2010 and December 2016 575 patients (343 males, 242 females) underwent IOC during LC for symptomatic cholecystitis due to cholelithiasis. Among patients accrued for the study, 143 underwent preoperative ERCP for suspicion of common biliary duct stones. At the time of pre-operative ERCP, 123 were found to have common biliary duct stones while 20 (15%) presented negative ERCP. Complete removal of stones was accomplished in 119 patients. Among these patients, 13 had residual common biliary duct stones diagnosed by IOC (11%). Two patients underwent laparoscopic bile duct revision and, last, two patients were referred for ERCP at a later point. It is of note that all patients who presented residual stones by IOC had undergone pre-operative sphincterotomy. This study demonstrates that IOC is particularly effective in detecting residual stones in patients undergoing LC in sequential treatment of common biliary duct and/or gallbladder stones, and may be used on a routine basis in the sequential treatment of cholecystocholedocholithiasis.

1 May 2011
Verified
Journal Article
Closed access
MCM Catani
M Catani
RMR De Milito
R De Milito
FRF Romagnoli
F Romagnoli
PMP Mingazzini
P Mingazzini
VSV Silvestri
V Silvestri
CMC Modini
C Modini

28 July 2023 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
VSVania Silvestri
Vania Silvestri
EPEmanuele Pontecorvi
Emanuele Pontecorvi
ASAntonio Sciuto
Antonio Sciuto
DPDaniela Pacella
Daniela Pacella
RPRoberto Peltrini
Roberto Peltrini
FCFrancesco Corcione
Francesco Corcione

30 March 2020 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
UBUmberto Bracale
Umberto Bracale
GMGiovanni Merola
Giovanni Merola
ARAntonia Rizzuto
Antonia Rizzuto
EPEmanuele Pontecorvi
Emanuele Pontecorvi
VSVania Silvestri
Vania Silvestri
FCFrancesco Corcione
Francesco Corcione

1 September 2020 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
RPRoberto Peltrini
Roberto Peltrini
EPEmanuele Pontecorvi
Emanuele Pontecorvi
VSVania Silvestri
Vania Silvestri
CBCarolina Bartolini
Carolina Bartolini
MDMichele D’ambra
Michele D’ambra
FCFrancesco Corcione
Francesco Corcione